Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14341350 | 0.82 | MEN1 (0.56) | MEN1KMT2AHTR5AKDM1AOPRM1 | |
| SCHEMBL14341349 | 0.82 | MEN1 (0.56) | MEN1KMT2AHTR5AKDM1AOPRM1 | |
| SCHEMBL3968577 | 0.82 | MEN1 (0.56) | MEN1KMT2AHTR5AKDM1AOPRM1 | |
| SCHEMBL13435155 | 0.77 | ALOX15 (0.52) | KMT2ACXCR3HSD11B1 | |
| SCHEMBL5163788 | 0.77 | OPRL1 (0.53) | CXCR3OPRM1 | |
| Hydrochloric Acid SCHEMBL5165885 | 0.76 | OPRL1 (0.54) | CXCR3OPRM1 | |
| SCHEMBL8029953 | 0.75 | MEN1 (0.54) | MEN1KMT2AHTR5AKDM1AOPRM1 | |
| SCHEMBL3856093 | 0.71 | MEN1 (0.68) | MEN1KMT2AHTR5AKDM1AOPRM1 | |
| SCHEMBL8468658 | 0.71 | MEN1 (0.61) | MEN1KMT2AHTR5AKDM1AOPRM1 | |
| SCHEMBL8468660 | 0.71 | MEN1 (0.61) | MEN1KMT2AHTR5AKDM1AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687644-B2 | Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-30 | — | — | US | disclosed |
| US-7687644-B2 | Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-30 | — | — | US | disclosed |
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | HSD11B1, HSD11B2, HSDL2 | MEN1 1910/4885KMT2A 3591/4885CXCR3 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.